In addition to second-site mutations at the dimer interface, the authors identified resistant mutations in IDH that interfere with NADPH binding and confirmed their presence in cases of IDH2R140Q mutant AML patients that developed resistance to Enasidenib [102]. The gene discussed is IDH1; the disease is acute myeloid leukemia.